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expressions of CXCL12 variants and CXCR4 in
human critical leg ischemia
Teik K. Ho, MRCS, PhD,a Janice Tsui, MD, FRCS,a Shiwen Xu, PhD,b Patricia Leoni, PhD,b
David J. Abraham, PhD,b and Daryll M. Baker, PhD, FRCS,a London, United Kingdom
Purpose: Critical leg ischemia (CLI) is associated with a high morbidity and mortality. Therapeutic angiogenesis is still
being investigated as a possible alternative treatment option for CLI. CXCL12, a chemokine, is known to have two spliced
variants, CXCL12 and CXCL12, but the significance remains unknown. The study investigated the angiogenic effects
of CXCL12, protein expressions of CXCL12, and the receptor CXCR4 in human CLI.
Methods: In vitro, human microvascular endothelial cells (HMEC-1) were used. Cell proliferation was assessed using
methylene blue assay and cell count method. Apoptosis was determined by counting the pyknotic nuclei after
4=-6-diamidino-2-phenylindole staining and confirmed by caspase-3 assay. We employed matrigel as capillary tube
formation assay. The activity of signaling pathways was measured usingWestern blotting. In vivo, gastrocnemius biopsies
were obtained from the lower limbs of patients with CLI and controls (n  12 each). Immunohistochemistry, double
immunofluorescence labeling, and Western blotting were then performed.
Results: CXCL12 attenuated HMEC-1 apoptosis (P < .01), stimulated cell proliferation (P < .05) and capillary tube
formation (P < .01). Compared with CXCL12, CXCL12 has a greater effect on apoptosis and cell proliferation (P <
.01). Treatment with both variants resulted in time-dependent activation of PI3K/Akt and p44/42 but not p38 MAP
kinase. In CLI, CXCL12 was expressed by skeletal muscle fibers with minimal expression of CXCL12. CXCR4 was
extensively expressed and colocalized to microvessels. A significant 2.6-fold increase in CXCL12 and CXCR4 expres-
sions (P < .01) were noted in CLI but not for CXCL12 (P > .05).
Conclusions:The study showed that CXCL12 hadmore potent angiogenic properties but was not elevated in humanCLI
biopsies. This provided an interesting finding on the role of CXCL12 variants in pathophysiologic angiogenic response
in CLI. (J Vasc Surg 2010;51:689-99.)
Clinical Relevance: The in vitro study showed that CXCL12 had more potent angiogenic properties compared to
CXCL12, and both of these act via the p44/42 and PI3K/Akt pathways. The in vivo data using tissues of human CLI
confirmed the pathophysiological changes that showed deficient CXCL12 and the increased expression of CXCR4 by
microvessels, suggesting that CXCL12 plays an important role in human CLI. Therefore, the use of CXCL12 as a
proangiogenic agent may be more likely to provide encouraging results in future experiments and possibly in the use as
a possible therapeutic angiogenic agent.The incidence of critical leg ischemia (CLI) is re-
ported to be between 500 and 1000 per million people
per year, and the primary leg amputation rate in these
patients remains high, ranging from 10% to 40%.1 In
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doi:10.1016/j.jvs.2009.10.044patients with CLI, arterial insufficiency results in chronic
muscle ischemia and hypoxia, a stimulus for angiogene-
sis. The growing interest in the physiologic mechanisms
that regulate the formation of new blood vessels has led
to the use of angiogenic factors to stimulate the forma-
tion of new blood vessels in underperfused tissues, oth-
erwise known as therapeutic angiogenesis, to provide an
alternative treatment for CLI. It is therefore vital to
understand the pathophysiologic angiogenic response,
which occurs in the critically ischemic limb. We have
previously demonstrated an increased angiogenic re-
sponse and increased expression of hypoxia inducible
factor (HIF)–1 in CLI.2,3 One of the major angiogenic
proteins upregulated by HIF–1 is stromal cell-derived
factor (SDF)–1, also known as CXCL12.
CXCL12 is the only member of the -chemokines that
does not possess the conserved Glu-Leu-Arg motif preced-
ing the first cysteine residue, also called the ELR motif, but
has angiogenic activity. A previous study4 has identified
CXCL12 and its receptor CXCR4 as critical mediators for
689
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cells for neovascularization. In addition, CXCL12 had been
shown to be angiogenic in various tumors.5,6 Two human
CXCL12 splice variants, CXCL12 and CXCL12, have
been reported to date.7,8 Both of these splice variants have
identical amino acid sequences except for the presence of an
additional four amino acids at the carboxy terminus of
CXCL12.8 The importance of these variants remains
largely unknown. Most studies to date do not differentiate
between the CXCL12 variants.
CXCL12 exerts its biologic effects by binding only to
the cognate receptor CXCR4, a specific G protein-coupled
receptor.9 The interaction between CXCL12 and CXCR4
has been shown to activate the mitogen-activated protein
kinases (MAPK), extracellular signal-regulated kinase-1/2
(ERK-1/2 or also known as p44/42), as well as protein
kinase B (Akt), phosphatidylinositol 3(PI3)-kinase in vari-
ous cell types,10-13 but little is known about human micro-
vascular endothelial cells. CXCR4 is expressed by various
cell lines, including muscle cell lines, endothelial cells,
leucocytes, and progenitor cells,9,14-16 and the expression
of CXCR4 receptor on endothelial cells has been reported
to be regulated by hypoxia.17,18
In this study, because the specific functions of the splice
variants remain unclear, we hypothesize that CXCL12-
spliced variants have different angiogenic effects and that
the expression of CXCL12-spliced variants are increased in
human CLI. The aim of the study is to investigate the
angiogenic potentials of both CXCL12 and CXCL12
and to investigate the major transduction pathways,
which are activated by CXCL12. To determine the
pathophysiologic expressions of CXCL12 variants and
the cognate receptor CXCR4 in CLI, the expression of
these proteins in critically ischemic human skeletal mus-
cle is also examined.
METHODS
Test reagents. CXCL12 100 ng/mL; CXCL12
100 ng/mL; (R&D, Abingdon, UK)MEK inhibitors (Cell
Signaling Technology, Beverly, Mass): U0126 (U; 10
mol/L) and PD98059 (PD; 30 mol/L); wortmannin
(W; 10 mol/L), and LY294002 (Ly; 10 mol/L);
SB203580 (SB; 30 mol/L) (Calbiochem, San Diego,
Calif).
Cell culture. Human microvascular endothelial cells
(HMEC-1)19 were a gift from Professor J Pearson (Kings
College, London, UK). The cells from passages 10 to 12
were maintained in standard endothelial cell growth me-
dium (M199/ECGS/heparin/20% FCS). For experi-
ments, HMEC-l were cultured in endothelial cell basal
medium (EBM; BioWhittaker, Walkersville, Md), 10% fetal
calf serum (FCS), 2 mmol/L L-glutamine, 1 mmol/L
sodium pyruvate, 100 units per mL penicillin, and 100 g
permL streptomycin at 37°C in 5%CO2 in air. The viability
of cells was determined after experiments as appropriate by
exclusion studies using Trypan blue.
Cell proliferation. Cell proliferation was quantified
using cell count method and methylene blue assay as pre-viously described20,21 following a dose-response curve to
determine the optimum dose of CXCL12 and CXCL12.
Cell count method:20 HMEC-1 were seeded onto six-well
polystyrene plates. HMEC-1 proliferation was determined
on days 0 and 3 by hemocytometer analysis of a trypsinized
aliquot of cells. Methylene blue assay:21 HMEC-1 were
seeded onto 96-well plates for 72 hours, fixed overnight
with formol saline, and stained with 1% methylene blue in
0.01 M borate buffer (pH 8.5) 30 minutes followed by
washing with 0.01 M borate buffer. To elute the dye,
ethanol and 0.1M HCl (1:1 ratio) were used. The absor-
bance of each well at 650 nm was measured by a microplate
reader.
Induction and quantification of apoptosis. To de-
termine the survival effect exerted by CXCL12 and
CXCL12 on HMEC-1, apoptosis was induced using a
serum deprivation method as previously described.22,23
Culture medium was removed and replaced with endothe-
lial basal medium (EBM) without any supplement or
treated with test reagents. After 24 hours of serum depri-
vation, the proportion of apoptotic HMEC-1 was deter-
mined by manually counting pyknotic nuclei after 4=-6-
diamidino-2-phenylindole (DAPI; Sigma, Dorset, UK)
staining. DAPI-stained pyknotic nuclei were counted as
percentage of 100 cells in each well. Apoptosis was further
determined using caspase-3 assay by Western blotting as
described below.
Activation of signaling pathways involved in cell
proliferation and apoptosis. To assess the effect of
CXCL12 on the stimulation of signaling pathways,
CXCL12 and CXCL12 were added to cells using the
method as previously described.24 Briefly, cells were seeded
and grown to confluence in culture medium in six-well
plates. The medium was replaced with EBM and incubated
overnight to allow the cells to become quiescent. To ascer-
tain the effect of CXCL12 and CXCL12 on the stimu-
lation of the signaling pathways, cells were stimulated with
100 ng/mL of CXCL12 and 100 ng/mL of CXCL12
for up to 24 hours. Where appropriate, cells were incubated
with inhibitors for 45 minutes before the addition of
CXCL12 and CXCL12. The activities of the inhibitors
were verified by examining their ability to block phosphor-
ylation of Akt, p44/42, and p38 pathways. The cells were
collected at various time points, 0 minute, 1 minute, 10
minutes, 30 minutes, 1 hour, 8 hours, 16 hours, and 24
hours poststimulation and washed three times with ice-cold
PBS and mixed with 200 L of 4 loading buffer (20%
sodium dodecyl sulphate [SDS] 1M Tris HCl pH 6.8, 
mercaptoethanol, glycerol, deionized water, and 0.2% bro-
mophenol blue). The cells were then removed using a
sterile cell scraper and lysed by using a 23G needle three
times. Following that, the cells were heated at 95oC for 5
minutes to denature active enzymes before analysis by
Western blotting.
Matrigel assay and quantification of tube for-
mation. Growth factor-reduced matrigel25 (BD Bio-
sciences, Bedford, UK) was applied to six well plates as per
manufacturer instructions. HMEC-1 were then plated
ascular
re ind
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without test reagents. The tube formations were assessed
using previously described methods.26,27 Two blinded ob-
servers assessed the morphology of the tubes.26 Tube for-
mation in the presence of test reagents was compared with
tube formation in EBM alone as a negative control and 10%
FCS as a positive control. The area of the tube network was
quantified at 40 magnification with a Nikon microscope
and camera. The images were then analyzed using a Na-
tional Institutes of Health (NIH) image system.27 Each
reagent was tested in triplicate, and each experiment was
repeated at least three times.
Western blot analysis. Western blot analysis was per-
formed as previously described.24 Briefly, HMEC-1 lysates
were resolved by SDS-PAGE and electrotransferred to
Hybond-C Extra nitrocellulose membrane (Amersham
Biosciences, Bucks, UK). Protein loading was checked by
measuring glyceraldehyde-3-phosphate (GAPDH) using
anti-GAPDH antibody (Santa Cruz Biotechnology, Santa
Cruz, Calif). Activated caspase-3, Akt, phospho-Akt
(Ser473), p38, phospho-p38 (Thr180/Tyr182), p44/42,
and phospho-p44/42 (Thr202/Tyr204) were detected
using antibodies as described by the manufacturer (Cell
Signaling Technology, Beverly, Mass). Protein bands were
detected by chemoluminescence using ECL Western blot-
ting detection reagent (AmershamBiosciences, Little Chal-
font, Buckinghamshire, UK).
Patients and skeletal muscle specimens. Patients un-
dergoing peri-genicular amputation for chronic CLI (CLI
group, n 12) and great saphenous vein harvesting during
coronary artery vein graft bypass (control group, n  12)
were recruited with the approval of a local research ethical
committee. Significant peripheral arterial disease in the
control group were excluded on clinical history and exam-
ination as well as ankle-brachial pressure index (ABPI) in
which patients with ABPIs 0.9 were excluded. Both
groups, control and CLI, were matched in terms of major
cardiovascular risk factors (Table). During surgery, a sepa-
rate incision was performed to obtain the gastrocnemius
muscle biopsy before amputation. The muscle samples
Table. Patient characteristics
Control, n  12
Mean age 69.17  9.77
Male:female 11:1
Diabetes mellitus 6
Hypertension 4
Cigarette smoking 5
Hypercholesterolemia 8
Statin therapy 8
Aspirin therapy 10
CLI, Critical leg ischemia.
aUnpaired t test.
bMann-Whitney U test.
Both groups, control and CLI, were matched with regard to major cardiov
excluded on clinical history and examination as well as ankle-brachial pressuwere snap frozen immediately within 10 to 15 seconds withliquid nitrogen and stored at 80oC until further analysis.
For immunohistochemistry and immunofluorescence
stainings, the muscle samples were fully embedded in Tis-
sue-Tek OCT compound (Bright Instrument, Hunting-
don, UK) on cork discs and frozen immediately with liquid
nitrogen.
Skeletal muscle proteins were isolated using a modifi-
cation of the method previously described.28 Frozen mus-
cle samples were mechanically homogenized using a glass
mortar homogenizer fitted with a Teflon pestle at 4oC in 10
volume of urea lysis buffer (8M urea, 40mM Imidazol, pH
7.0, 2 mMEGTA, 1mMMgCl2, 6MKCl, and 2mMATP
in the presence of Complete protease inhibitors (Roche
Diagnostics, Mannheim, Germany) and phosphatase inhib-
itors cocktails I and II (Sigma, Poole, Dorset, UK). After
homogenizing, the samples were centrifuged in a refriger-
ated Eppendorf centrifuge for 30 minutes at 13,000 rpm.
The supernatants were collected and analyzed by SDS-
PAGE and Western blots as described above using the
following primary antibodies, anti-CXCL12 (clone
79014.111, R&D Systems, Minneapolis, Minn), anti-
CXCL12 (Peprotech, Rocky Hill, NJ), and anti-CXCR4
(clone 12G5; BD Biosciences, Oxford, UK). The bands
were quantified using densitometry.
Immunohistochemistry and immunofluorescence
double labeling. Immunohistochemistry and immuno-
fluorescence double labeling were performed as previously
described.3 Immunohistochemistry was performed using
the avidin–biotin– complex (ABC) peroxidase method.
Primary antibodies used were 10 g/mL of anti-
CXCL12 (clone 79014.111; R&D Systems) and 1.5
g/mL of anti-CXCL12 (Peprotech). To investigate co-
localization between cell-specific antigens, double immu-
nofluorescence labeling was carried out.
Statistics. All in vitro experiments were performed in
triplicates and repeated three times. Multiple comparisons
among three groups or more used ANOVA. Student t test
was used to compare means between two groups. All data
were expressed in mean  SD. Mann-Whitney U test was
LI, n  12 Difference between two groups, P value
.09  5.74 aP 	 .05
11:1 bP 	 .05
7 bP 	 .05
6 bP 	 .05
5 bP 	 .05
9 bP 	 .05
7 bP 	 .05
11 bP 	 .05
risk factors. Significant peripheral arterial disease in the control group was
ex (ABPI) in which patients with ABPIs 0.9 were excluded.C
70used to compare nonparametric data.
n  s
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Effects of CXCL12 on cell proliferation. Following
a dose-response curve, the optimum concentration of
Fig 1. Effects on cell proliferation by CXCL12 and CX
of 100 ng/mL was used for CXCL12 and CXCL12. B
133 12.33 103 by CXCL12 and 156.17 19.13
is further confirmed by methylene blue assay (C), with
treated with CXCL12 and CXCL12, respectively. In
significantly higher compared with that of CXCL12 (P
abrogated cell proliferation (P .01), indicating that cell
the p44/42 signaling pathway. Values expressed as meaCXCL12 andCXCL12 used was 100 ng/mL (Fig 1,A).Both CXCL12 and CXCL12 stimulated HMEC-1 pro-
liferation (Fig 1). Using the cell count method, the mean
number of cells SD on day 3 of proliferation increased to
2. A,Dose-response curve showing the optimum dose
ll count method demonstrated increased cell number to
by CXCL12 on day 3 of proliferation (P .05). This
ptical density of 0.87  0.07 and 1.05  0.05 for cells
methods, the increase in cell number to CXCL12 was
1). D, The addition of U0126 (U) and PD98059 (PD)
feration was stimulated by CXCL12 and CXCL12 via
tandard deviation (SD). Error bars represent SD.CL1
, Ce
 103
the o
both
 .0
proli133 103 12.33 and 156.17 103 19.13 in response
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Volume 51, Number 3 Ho et al 693Fig 2. Antiapoptosis effects of CXCL12 and CXCL12 on HMEC-1. A, HMEC-1 underwent apoptosis after 24
hours of serum deprivation. The apoptotic cells were demonstrated by dense white nucleus after staining with DAPI.
B, The percentage of apoptotic cells treated by CXCL12 was 12.49  2.69%, and CXCL12-treated cells had
apoptosis of 9.77  1.58%. Both of these were significantly lower compared with untreated cells in EBM 28.2  4.3
(P  0.01). In addition, the effect of CXCL12 was observed to be more significant compared with CXCL12 (P 
.01). C,Western blot analysis of caspase-3 activation revealed that both CXCL12 and CXCL12 have antiapoptotic
effect, with CXCL12 having a greater effect (P  .01). Bar graphs in relative density unit, RDU; EBM 0.21  0.04
vs CXCL12 0.66  0.07 vs CXCL12 0.27  0.04. Full-length and activated fragments of the caspase-3 were seen
at molecular weights of 35 kDa and 17 kDa, respectively. Jurkat cells treated with 25 M etoposide were used as a
molecular weight control. GAPDH was used as a loading control. D, Antiapoptotic effects were reversed with the
addition of wortmannin (W) and LY294002 (LY), both PI3K inhibitors (P .01). Therefore, the antiapoptotic effects
of both CXCL12 and CXCL12 were via the PI3K/Akt pathway. Values are expressed as mean  SD. Error bars
represent standard deviation. Scale bar  100 m.
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March 2010694 Ho et alFig 3. Effects of CXCL12 and CXCL12 on capillary tube formation. A,HMEC-1 formed capillary tubes on matrigel
assay after 24-hour culture in 10% FCS, CXCL12, and CXCL12.B, Both CXCL12 and CXCL12 promoted capillary
tube formations (P .05). Although the area of tube networkwas higher in cells treatedwithCXCL12, this was not found
to be statistically significant compared with CXCL12 (MeanODCXCL12, 6.22 1.58 vs CXCL12 7.19 1.71, P
.29).C, CXCL12-induced angiogenesis was inhibited by the addition of U0126 and PD98059 as well as wortmannin and
LY294002 (P .01). Values are expressed as mean SD. Error bars represent standard deviation. Scale bar 50 m.
. NS,
02; SB
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B). The increase in cell number in response to CXCL12 is
significantly higher compared with that of CXCL12 (P
.01). This is further confirmed bymethylene blue assay (Fig
Fig 4. Time-dependent activation of signaling pathways.
and Akt reachedmaximum around 10minutes after treatme
by 24 hours. The p38 signaling pathway was not activated.
loading in each well. The bar graphs showed the relative am
total proteinsmeasured in %RDU.Grey bar represented stim
CXCL12.B,To verify specificity of inhibitors used, cells w
absence of inhibitors. Protein extracts were then prepare
phospho–p38/Akt/p44/42 and total–p38/Akt/p44/42
PD, PD98059;U, U0126;W, Wortmannin; LY, LY29401, C).Antiapoptosis effects of CXCL12. Following serum
deprivation for 24 hours, HMEC-1 underwent apoptosis as
demonstrated by dense white nucleus after staining with
DAPI (Fig 2, A). Both the CXCL12 variants significantly
estern blot analysis showed that the activation of p44/42
th CXCL12 andCXCL12 and returned to basal activity
protein for p38, Akt, and p44/42 confirmed equal sample
t of phospho-p38, Akt, and p44/42 to the corresponding
on byCXCL12, andwhite bar represented stimulation by
eated with CXCL12/ for 10minutes in the presence or
d subjected to Western blot analysis with antibodies to
nonstimulated cells at 0 min; RDU, relative density unit;
, SB203580.A, W
ntwi
Total
oun
ulati
ere tr
d anattenuated the extent of apoptosis (P  .01) (mean  SD
JOURNAL OF VASCULAR SURGERY
March 2010696 Ho et alFig 5. In vivo CXCL12 and CXCR4 expressions in CLI. CXCL12 was widely expressed in skeletal muscle fibers, A (i),
but CXCL12 expression was not detected on the sections, A (ii). The distribution of CXCR4 expressions corresponded
with that of microvessels,A (iii). Immunofluorescence double-labeling demonstrating CXCR4 labeled with FITC (green),
B (i) and CD31 labeled with Texas red (red), B (ii). Colocalization of CXCR4 and CD31 was viewed as yellow under
confocal microscopy,B (iii).C, Skeletal muscle homogenates from both control and CLI groups were analyzed byWestern
blot analysis. The samples were run individually for each of the patient samples, and a representative figure shown.Compared
with controls (n 12), the CLI group (n 12) showed increased CXCL12 (control vs CLI; 3.14 0.34 vs 8.77 1.48
RDU, P .01),C (i) and CXCR4 (control vs CLI; 1.50 0.31 vs 5.41 0.87 RDU, P .01),C (iii) expressions. There
was no significant difference in CXCL12 expression between the two groups,C (ii), (control vs CLI; 0.96 0.14 vs 1.09
 0.16 RDU, P .06). actin was used as a control for sample loading,C (iv). Values are expressed as mean SD. Error
bars represent standard deviation. RDU, relative density unit. Scale bar 100 m.
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12.49 2.69% vs CXCL12 9.77 1.58%; Fig 2, B). The
antiapoptosis effect of CXCL12 was also observed to be
more significant compared with CXCL12 (P  .01).
These findings were confirmed by investigating the state of
caspase-3 activation in the cell lysates. The activated frag-
ment of caspase-3 has a molecular weight of 17 kDa.
Western blot analysis of caspase-3 activation revealed that
both CXCL12 and CXCL12 have an antiapoptotic ef-
fect, with CXCL12 having a greater effect (P  .01)
(relative density unit, [RDU]; EBM 0.21  0.04 vs
CXCL12 0.66  0.07 vs CXCL12 0.27  0.04; Fig 2,
C). Jurkat cells treated with 25 M etoposide (Cell Signal-
ing Technology, Beverly, Mass) were used as a molecular
weight control.
Effects of CXCL12 on capillary tube formation.
HMEC-1 formed capillary tubes on Matrigel assay after 24
hours of culture in 10% FCS, CXCL12, and CXCL12
(Fig 3, A). Both CXCL12 and CXCL12 stimulated
capillary tube formation (EBM 2.75  0.83 vs CXCL12
6.22 1.58 vs CXCL12 7.19 1.71; P .01, Fig 3, B),
and the capillary tube area network was higher after stimu-
lation with CXCL12, but this was not statistically signifi-
cant, P  .29.
Time-dependent activation of signaling pathways.
Activation of p44/42 and Akt reached maximum around
10 minutes after treatment with CXCL12 and CXCL12
and returned to basal activity after 24 hours, whereas p38
was not activated as shown by Western blot analysis using
antibodies specific for the phosphorylated form of p44/42,
Akt, and p38 (Fig 4, A).
To investigate the effects of these pathways on cell
proliferation and antiapoptosis by both variants of
CXCL12, inhibitors to these pathways were added to the
cell proliferation and apoptosis assays. The specificity of the
inhibitors was verified as demonstrated in Fig 4, B. The ad-
dition of U0126 and PD98059 abrogated cell prolifera-
tion, indicating that both CXCL12 and CXCL12 stim-
ulated cell proliferation via the p44/42 signaling pathway
(Fig 1,D). The antiapoptotic effect of CXCL12 variants on
HMEC-1was reversed by the addition of both wortmannin
and LY294002, PI3K inhibitors (Fig 2, D). The inhibitors
to these pathways were further added to the matrigel assay
to investigate CXCL12-induced angiogenesis. CXCL12-
induced angiogenesis was inhibited by the addition
of U0126 and PD98059 as well as wortmannin and
LY294002 (Fig 3, C).
In vivo CXCL12 and CXCR4 expressions. In criti-
cally ischemic human skeletal muscle, CXCL12 was ex-
pressed in skeletal muscle fibers, whereas there was minimal
expression of CXCL12 [Fig 5, A (i) and A (ii)]. The
distribution of CXCR4 expressions corresponded with that
of microvessels [Fig 5, A (iii)], and this was confirmed by
immunofluorescence double labeling, with the microves-
sels labeled with anti-CD31 (clone JC70) [Fig 5, B (i, ii,
and iii)].
Skeletal muscle homogenates from both control and
CLI groups were analyzed by Western blot analysis (Fig 5,C). Compared with controls, the CLI group showed in-
creased CXCL12 (control vs CLI; 3.14 0.34 vs 8.77
1.48 RDU, P  .01) and CXCR4 (control vs CLI; 1.50 
0.31 vs 5.41  0.87 RDU, P  .01) expressions [Fig 5, C
(i) and C (iii), respectively]. There was no significant
difference in CXCL12 expression between the two groups
[Fig 5, C (ii), control vs CLI; 0.96  0.14 vs 1.09  0.16
RDU, P  .06]. actin was used as control for sample
loading [Fig 5, C (iv)].
DISCUSSION
CXCL12 is an important chemokine in angiogenesis,
which acts via the recruitment of endothelial progenitor
cells to the ischemic peripheral tissues.4 Nevertheless, little
data are available on the direct angiogenic effects of
CXCL12, especially the roles of the different variants,
CXCL12 and CXCL12. This study examined these
effects.
The in vitro data confirmed the direct angiogenic prop-
erties of CXCL12. Matrigel assay mimicking various steps
in angiogenesis, such as migration and differentiation, rep-
resented the angiogenic process in the capillary tube forma-
tion. CXCL12 was shown to stimulate cell proliferation
and exerted a survival effect on HMEC-1 more effectively
compared with CXCL12. This difference in activity could
possibly be attributed to the differential processing of these
proteins, which reduced the affinity of CXCL12 to bind
to cells.29 In addition, a previous study30 showed different
C-termini of CXCL12 variants may contain important mo-
lecular determinants for differences in biologic functions.
This may affect binding of CXCL12 to cells either via the
receptor CXCR4 or heparin sulphate, a glycosaminogly-
can found ubiquitously in cell surfaces. The binding of
CXCL12 to glycosaminoglycans, both on the cell surface
and bound to the extracellular matrix, is believed to be
important for chemokine function, presumably because it
provides a means for achieving enhanced concentrations of
immobilized CXCL12 available for binding to CXCR4.31
In examining cell proliferation, the periodic cell count
method was utilized because previous thymidine incorpo-
ration studies had yielded conflicting data.32-34 They were
limited to detect S phase perturbations and contain techni-
cal pitfalls including extranuclear binding of thymidine,
dependence on cellular uptake, metabolism of thymidine in
the cell, and problems with the physicochemical properties
of [3H] thymidine.35 Methylene blue assay was used to
validate the results of cell proliferation.21
CXCL12/CXCR4 interactions trigger several intracel-
lular signals in different cell types and functions, such as
increases in cytosolic calcium ion flux, p44/42 phosphor-
ylation, activation of PI3K/Akt, tyrosine phosphorylation
of focal adhesion complex components such as Pyk-2 and
Crk, and increases in NF-B activity.36 These highlight the
complexity of CXCL12-mediated signaling depending on
the cell type and experimental conditions. Previously, little
was known about the effects of HMEC-1 stimulation by
CXCL12 variants. Our data showed that the proliferative
effect and antiapoptotic effect on HMEC-1 were via the
JOURNAL OF VASCULAR SURGERY
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the CXCL12 variants stimulated these pathways in a time-
dependent manner.
In the skeletal muscle biopsies, areas of tissue necrosis
and surrounding inflammation were avoided in an attempt
to avoid the influences of these confounding factors. The
tissues were viable, confirmed by the presence of nuclei in
the myocytes and intact morphology of skeletal muscle
microscopically. Both the groups were matched in major
cardiovascular risk factors, thereby eliminating the possible
confounding effects of these factors. Therefore, the differ-
ence observed in the results of our study were attributed to
the presence of ischemia in the CLI group.
CXCL12 had been shown to be expressed in skeletal
muscle fibers, whereas CXCL12 had been localized to
microvasculature in inflammatory myopathies.37 In this
study, CXCL12 expression was increased and localized to
muscle fibers in CLI. This finding suggested that skeletal
muscle fibers may have an important role in the pathophys-
iological response in CLI, either in the angiogenic response
or the adaptation of skeletal muscle metabolism in the
hypoxic state. It had been reported that CXCL12 improved
cardiac function of infarcted myocardium via angiogenesis
in a murine model.38 Ceradini et al4 demonstrated a role of
CXCL12 in homing to circulating progenitor cells in a
murine ischemia model. Blockade of CXCL12 in the host
resulted in a dramatic reduction in the number of infused
progenitor cells that were recruited to ischemic tissue and
decreased the resultant neovascularization and blood flow.
It was plausible that CXCL12 expressions by the skeletal
muscle fibers act indirectly to stimulate angiogenesis via
trafficking and recruitment of endothelial progenitor cells
to the ischemic limbs.
However, the lack of CXCL12 expression in CLI,
either in microvasculature or muscle fibers, may suggest
that the lack of CXCL12 can possibly contribute to the
inadequate angiogenic response leading to CLI and the
associated high amputation rate that occurs in patients with
CLI.1 In addition, the microvessels in CLI were previously
shown to have abnormal ultrastructure and deficient arte-
rialization,2 and we further hypothesize that deficiency in
appropriate proangiogenic factors such as CXCL12 may
exacerbate the pathology. The lack of CXCL12 expres-
sion in our study may be explained by its transient expres-
sion39 because all the CLI samples were chronically isch-
emic. Furthermore, because CXCL12 and CXCL12 are
constitutively and ubiquitously expressed, the different
CXCL12 variant expressions as demonstrated in CLI tis-
sues can possibly be due to their degradation process as a
result of the difference in C-termini.29 On the contrary, the
lack of CXCL12 expression in CLI may suggest that
CXCL12 does not have a significant role in the patho-
physiologic response in CLI.
CXCR4 has been previously shown to be regulated by
hypoxia.17,18 Our study confirmed that CXCR4 expres-
sions were present in microvasculature of skeletal muscles
and increased in CLI. The double immunofluorescence
labeling confirmed the extensive expression of CXCR4 inthe microvessels of skeletal muscles. With the extensive
CXCR4 receptor present, this finding supported the poten-
tial use of CXCL12 in the treatment of peripheral vascular
disease. The clinical application of the CXCL12/CXCR4
axis had been shown by Carr et al40 to be possible. Systemic
administration of CXCL12 in a rat model of arterial insuf-
ficiency enhanced collateral blood flow above vehicle con-
trol after 2 weeks of treatment via direct effects on vascular
endothelial cells.
In conclusion, this study showed that in vitro,
CXCL12 had more potent angiogenic properties com-
pared with CXCL12, and both of these act via the p44/42
and PI3K/Akt pathways. The in vivo data using tissues of
human CLI confirmed the pathophysiologic changes that
involve CXCL12, strongly suggesting that CXCL12 plays
an important role in human CLI and may possibly act as a
good therapeutic target.
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